Moderna outlined its three-year strategic plan and pipeline developments during an Analyst Day presentation, projecting revenue growth reaching 10 percent in 2026 while making progress toward achieving cash flow breakeven by 2028.
The biotechnology company, led by CEO Stéphane Bancel, indicated its strategy centers on developing a robust seasonal vaccine portfolio for vulnerable populations while reinvesting generated revenue into cancer treatments and rare disease therapeutics. Revenue from currently marketed products including Spikevax, mRESVIA and mNEXSPIKE, along with anticipated launches in influenza, combination flu/COVID vaccines and Norovirus immunizations, will fuel investments in oncology and rare disease development programs.
The company’s commercial expansion strategy encompasses both geographical reach and new product introductions. Growth projections for 2026 include benefits from multi-year agreements with the United Kingdom, Canada and Australia that support research activities, enhance national security preparedness and generate predictable revenue through domestic manufacturing capabilities. Strong adoption of mNEXSPIKE domestically and international launches are also expected to contribute to growth.
European markets represent substantial opportunities in 2027 as a competing COVID contract concludes and additional product approvals are anticipated. Moderna also expects to enter the influenza vaccine market while exploring potential long-term partnerships across Latin America and Asia-Pacific regions.
By 2028, Moderna anticipates becoming first to market with a combined flu/COVID vaccine while maintaining growth momentum with its Norovirus vaccine candidate, potentially expanding its seasonal vaccine portfolio to six approved products. The company’s current commercial infrastructure supports these expansion plans through established channels with retail pharmacies, government entities and healthcare providers, with teams already operational in partnership countries.
The seasonal vaccine franchise is expected to grow from three approved products currently to potentially six by 2028. Nine Phase 2 and Phase 3 clinical studies are underway in the oncology portfolio, including three late-stage programs evaluating intismeran autogene.
Manufacturing optimization has been central to Moderna’s operational strategy. Since 2022, the company streamlined its production network by exiting eight contract manufacturing arrangements, announcing enhanced drug product capabilities domestically, and establishing three company-managed facilities internationally. Increased production volume, enhanced manufacturing efficiency and waste reduction across facilities are projected to improve gross margins by 10 percent over three years.
The Norwood, Massachusetts facility enables complete end-to-end production through automation, robotics and artificial intelligence integration, improving cost efficiency and minimizing waste. New fill/finish capabilities planned for 2027 will provide greater control, flexibility and speed.
International manufacturing sites in Laval, Harwell and Clayton enable local access to mRNA medicines and diversify revenue streams. These facilities are positioned to deliver growth with margins comparable to U.S. operations.
The Marlborough facility was specifically designed for intismeran, Moderna’s personalized neoantigen therapy. Built for speed and scalability with advanced automation, the site began producing clinical batches in September 2025 and is preparing for commercial launch while optimizing the manufacturing process to reduce turnaround times and costs.
Key pipeline programs include approved vaccines Spikevax, mNEXSPIKE and mRESVIA. The seasonal influenza vaccine mRNA-1010 submissions are expected to be completed by January 2026 across multiple regulatory jurisdictions. The combination flu/COVID vaccine mRNA-1083 is under European regulatory review with Canadian submission completed in 2025, while awaiting additional FDA guidance. The Norovirus vaccine Phase 3 study is enrolling a second season for additional data, with interim analysis expected in 2026.
Oncology programs include intismeran autogene, advancing through eight Phase 2 and Phase 3 trials in collaboration with Merck across multiple cancer types. The cancer antigen therapy mRNA-4359 continues Phase 1/2 evaluation including cohorts in metastatic melanoma and lung cancer.
Rare disease therapeutics include mRNA-3927 for Propionic Acidemia, which reached target enrollment in a registrational study, and mRNA-3705 for Methylmalonic Acidemia, selected for FDA’s START program with a registrational study planned for 2026.
Strategic prioritization led to discontinuation of four pipeline programs: the congenital Cytomegalovirus program mRNA-1647, herpes simplex virus program mRNA-1608, Varicella-Zoster virus program mRNA-1468, and Glycogen Storage Disease Type 1a program mRNA-3745.
Financially, Moderna expects up to 10 percent revenue growth in 2026 driven by international partnerships and mNEXSPIKE adoption. The company reduced expected cash costs for 2026 to approximately $4.2 billion and for 2027 to a range of $3.5 to $3.9 billion through disciplined cost management and research prioritization, while manufacturing improvements are projected to increase gross margins by more than 10 percentage points over three years.
Research and development investment allocation is shifting toward oncology and rare diseases as large infectious disease investments conclude. The balance sheet is positioned to fund investments through the targeted 2028 cash breakeven.
Moderna announced closing a five-year term loan facility with Ares Management Credit Funds providing up to $1.5 billion in non-dilutive financing, strengthening the balance sheet and providing additional flexibility. The company updated its 2025 projected year-end cash and investment balance to $7.1 to $7.6 billion, increased from previous expectations of $6.5 to $7.0 billion, reflecting a $0.6 billion initial loan draw.
The company continues advancing its mRNA technology platform to develop vaccines and therapeutics across infectious diseases, cancer, rare diseases and other areas, maintaining focus on delivering innovative medicines to patients globally.